| Colocalization of somatic and meiotic double strand breaks near the Myc oncogene on mouse chromosome 15. | None |
| During senescence, miR-34a targets the important proto-oncogene MYC and our data suggest that miR-34a thereby coordinately controls a set of cell cycle regulators | None |
| Driving gradual endogenous c-myc overexpression by flow-sorting: intracellular signaling and tumor cell phenotype correlate with oncogene expression. | None |
| Msh2-dependent mismatch repair function actively suppresses c-Myc-associated oncogenesis during early B cell development. | None |
| Stabilization of G-quadruplex DNA with platinum(II) Schiff base complexes: luminescent probe and down-regulation of c-myc oncogene expression. | None |
| the Igh 3_ regulatory region confers oncogenic activity by long-range and developmental stage-specific activation of translocated c-myc genes | None |
| UV damage and repair in the domain of the human c-myc oncogene. | None |
| Oncogene transformation frequency of nonsenescent SFME cells is increased by c-myc. | None |
| MYCN oncoprotein targets and their therapeutic potential. | None |
| Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. | None |
| The lethal giant larvae tumour suppressor mutation requires dMyc oncoprotein to promote clonal malignancy. | None |
| The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy. | None |
| Inducement of G-quadruplex DNA forming and down-regulation of oncogene c-myc by bile acid-amino acid conjugate-BAA. | None |
| Structure-based design of platinum(II) complexes as c-myc oncogene down-regulators and luminescent probes for G-quadruplex DNA. | None |
| Occurrence and expression of p53 suppressor gene and c-Myc oncogene in dog eyelid tumors. | None |
| data are presented showing that each risk locus bears epigenetic marks consistent with enhancer elements and forms a long-range chromatin loop with the MYC proto-oncogene located several hundred kilobases telomeric. | None |
| results reveal the presence of a hitherto unknown signaling feed-back loop between RhoA and c--Myc oncogenes that can contribute to maintain fluid cytoskeletal dynamics in cancer cells | None |
| Depletion of c-myc with specific antisense sequences reverses the transformed phenotype in ras oncogene-transformed NIH 3T3 cells. | None |
| The c-Myc target glycoprotein1balpha links cytokinesis failure to oncogenic signal transduction pathways in cultured human cells. | None |
| miR-22 acts as a tumor suppressor through direct repression of MYCBP expression and subsequent reduction of oncogenic c-Myc activities. | None |